Anti-obesity Drugs Market Size Worth USD 104.9 Billion by 2035 | Roots Analysis

The anti-obesity drugs, also known as weight loss drugs, encompass a range of pharmaceutical treatments designed to assist individuals in managing obesity and related conditions. They provide healthcare professionals with valuable tools to complement lifestyle interventions, such as diet and exercise.

Further, these drugs play a critical role in enhancing weight loss outcomes, particularly for patients with significant obesity-related comorbidities. Weight loss drugs also contribute to improved quality of life and can lead to reduced healthcare costs by preventing obesity-related complications.

Advancements in drug formulation and delivery systems, along with the integration of novel compounds have led to the emergence of more effective and safer anti-obesity medications. Additionally, the surge in telehealth services and digital therapeutics applications is facilitating better patient engagement and adherence to treatment regimens.

Competitive Landscape of Anti-obesity Drugs Market

The anti-obesity drugs market landscape features around 225 anti-obesity / weight loss drugs developed by more than 120 drug developers, worldwide. The anti-obesity drugs market is highly fragmented, featuring the presence of both established companies as well as emerging start-ups. Further, majority of the companies in the weight loss drugs market are presently headquartered in North America.

Anti-obesity Drugs Market Key Players

The anti-obesity drugs market report also includes profiles of key players in the anti-obesity domain: Adocia, AstraZeneca, Boehringer Ingelheim, CinFina Pharma, Eli Lilly, Gmax Biopharma, Hanmi Pharm, Jiangsu Hengrui Pharmaceuticals, Kallyope, Novo Nordisk, PegBio, Pfizer, QL Biopharm, Regeneron, Roche, Sciwind Biosciences, Viking Therapeutics, and Zealand Pharma.

It is interesting to note that, in April 2024, Eli Lilly expanded its injectable medicine manufacturing capabilities through the acquisition of Nexus Pharmaceuticals in Wisconsin, US.

Anti-obesity Drugs Market Regional Outlook

Based on the geographical regions, the anti-obesity drugs market can be segmented into four major regions, North America, Europe, Asia-Pacific and Latin America. Led by the US, North America is anticipated to capture the majority share of the anti-obesity drugs market in 2024. Further, the weight loss industry in Asia-Pacific is accounted to be the fastest-growing segment of the market. This is primarily due to the increased awareness and acceptance of obesity as a chronic disease in the region.

Key Report Takeaways

Presently, around125 players are engaged in the development of anti-obesity drugs; of these, around 55% players are headquartered in North America

A sizeable proportion (70%) of big pharma players have entered into various partnerships in order to expand their anti-obesity drug portfolios; followed by players (~20%) undertaking expansion initiatives

The anti-obesity drugs market is anticipated to grow at an annualized rate (CAGR) of 21.1%, till 2035; North America is expected to capture the majority share (~60%) of the market by 2035

Anti-obesity Drugs Market Segments

Based on the research, Roots Analysis has segmented the anti-obesity drugs market into Type of Molecule, Active Compound Used, Mechanism of Action, Type of Agonist, Action Pathway, Route of Administration, Geographical Regions, Sales Forecast and Key Players.

Anti-obesity Drugs Market, by Type of Molecule

Biologics

Small Molecules

Anti-obesity Drugs Market, by Active Compound Used

Tirzepatide

Semaglutide

Retatrutide

Survodutide

Cagrilintide and Semaglutide

Orforglipron

Liraglutide

Other Active Compounds

Anti-obesity Drugs Market, by Mechanism of Action

GLP-1 Agonist / GIP Agonist

GLP-1 Agonist / GCGR Agonist

GLP-1 Agonist

GLP-1 Agonist / Amylin Analogue

GLP-1 / GCGR / GIP Agonist

Other Mechanisms of Action

Anti-obesity Drugs Market, by Type of Agonist

Single-Agonist

Dual-Agonist

Tri-Agonist

Anti-obesity Drugs Market, by Action Pathway

Centrally Acting

Peripherally Acting

Centrally Acting and Peripherally Acting

Anti-obesity Drugs Market, by Route of Administration

Oral

Parenteral

Anti-obesity Drugs Market, by Geographical Regions

North America

Europe

Asia-Pacific

Latin America

About Roots Analysis

Roots Analysis is a global leader in the market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

Contact US

Gaurav Chaudhary

Email: Gaurav.chaudhary@rootsanalysis.com or sales@rootsanalysis.com